Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: HN · HNG (analogue, separate)
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Mitochondrial-derived peptide
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Experimental inhibition of BAX-associated apoptosis.
Evidence and critical reading
Reported scientific and empirical uses
Aging research · Mitochondrial research
Promoted as cytoprotection and in mitochondrial stacks; distinguish native peptide from analogues.
Human evidence
No clinical anti-aging intervention benefit established by the cited mechanistic paper.
Preclinical evidence
Cellular and isolated-mitochondrial experiments; antiapoptosis is not automatically beneficial in every tissue.
Critical reading and limitations
BAX interaction was studied mechanistically; it does not demonstrate lower mortality or dementia in human users.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
Human safety, interactions and cancer-context effects unresolved.
Sufficient human data are lacking for dosing, interactions and long-term safety in these uses.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Humanin · 3 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07678073 · Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal TransplantationRegistry status: RecruitingLast update posted: July 8, 2026Query verification: October 16, 2026
NCT06105229 · Clinical Value of Plasma Humanin in Acute Kidney InjuryRegistry status: UnknownLast update posted: October 27, 2023Query verification: October 16, 2026
NCT03431844 · Humanin Isoforms in Cardiac Muscle and Blood Plasma and Major Complications After Cardiac OperationRegistry status: CompletedLast update posted: August 5, 2020Query verification: October 16, 2026
Source issues and references
Maintenance table implies 30–45 mg/week while the box summarizes 5–20 mg/week. Neither is selected as a safe regimen. · manual07 · Page 34
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID12732850
Humanin peptide suppresses apoptosis by interfering with Bax activation.
Guo B, Zhai D, Cabezas E, Welsh K, Nouraini S, Satterthwait AC, Reed JC.
October 16, 2026
- R27
- manual07
2.pdf
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026